最新医学別冊　新しい診断と治療のABC55/呼吸器7　特発性肺線維症

出版社： 最新医学社
発行日： 2008-05-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 特発性肺線維症
電子書籍版： 2008-05-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC55/呼吸器7　特発性肺線維症

    ―目次―

    特集　特発性肺線維症

    第1章　概念・定義と疫学
    　概念
    　疫学

    第２章　病理・病態生理
    　病理
    　病態生理
    　病因

    第３章　診断
    　診断 公立陶生病院
    　検査
    　　(１)呼吸機能
    　　(２)血液検査
    　画像所見
    　鑑別診断

    第４章　管理・治療
    　管理・治療
    　薬物療法・選択基準
    　治療薬剤
    　　(１)ステロイド薬・免疫抑制薬
    　　(２）血管拡張薬
    　　(３）抗線維化薬
    　在宅酸素療法(NIPPVを含む)
    　理学療法
    　外科療法・肺移植
    　経過・予後

    第５章　ガイドライン

    座談会
    　特発性肺線維症の臨床−現状と課題−

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.17 掲載の参考文献
1) Hamman L, et al:Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 51:154-163, 1935.
PubMed
2) 泉 孝英:特発性肺線維症の臨床. 日内会誌 84 (9):1396-1406, 1995.
 
3) American Thoracic Society, European Respiratory Society:ATS/ERS international multidisciplinary collsensus classification of idiopathic interstitial pneumonia. Am J Crit Care Med 165 (2):277-304, 2002.
 
4) Hamman L, et al:Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp 74 (2):177-212, 1944.
 
5) Peabody J W Jr, et al:Hamman-Rich syndrome:analysis of current concepts and report of three precipitous death following cortisone and corticotropin[ACTH]withdrawal. Arch Intern Med 92 (6):806-824, 1953.
PubMed
6) Liebow A A, et al:Desquamative interstitial pneumonia. Am J Med 39 (3):369-404, 1965.
 
7) Liebow A A:New concepts and entities in pulmonary diseases. In:The Lung (Liebow AA, et al, eds), pp332-365. Williams and Wilkins, Baltimore, 1967.
 
8) Crystal R G, et al:Idiopathic pulmonary fibrosis:Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 85 (6):769-788, 1976.
PubMed
9) Carrington C B, et al:Natural history and treated course of usual and desquamative interstitial pneumonia. N Eng J Med 298 (15) 801-809, 1978.
 
10) American Thoracic Society:Idiopathic pulmonary fibrosis:Diagnosis and treatment:International consensus statement. Am J Respir Crit Care Med 161 (2):646-664, 2000.
 
11) Epler G R, et al:Bronchiolitis obliterans oraganizing pneumonia. N Engl J Med 312 (1):152-158, 1985.
 
12) Davison A G, et al:Cryptogenic organizing pneumonitis. Q J Med 52 (207):382-394, 1983.
PubMed
13) Katzenstein A-L A, et al:Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 10 (4):256-267, 1986.
PubMed
14) Yousem S A, et al:Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 64 (11):1373-1380, 1989.
PubMed
15) Katzenstein A-L A, et al:Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 18 (2):136-147, 1994.
PubMed
16) Nagai S, et al:Nonspecific interstitial pneumonia:areal clinical entity? Clin Chest Med 25:705-715, 2004.
 
17) Travis W D, et al:ldiopathic nonspecific interstitial pneumonia Report of an ATS project. Am J Respir Crit Care Med (in press)
 
18) 泉 孝英:線維化性間質性肺炎-特発性間質性肺炎・肺線維症を中心に-. 日胸疾会誌 27 (11):1268-1273, 1989.
 
19) 泉 孝英:IIPとIPFの鑑別診断. 呼吸18 (2):201-207, (3):334-341, 1999.
 
20) 長井苑子, 他 監訳:米国胸部学会ガイドライン間質性肺疾患診療ガイドライン. 医学書院, 2003.
 
21) 貫和敏博:間質性肺炎. 日内会誌91 (11):1753-1759, 2002.
 
P.24 掲載の参考文献
1) 近藤有好, 他:原因不明のびまん性間質性肺炎, 肺線維症の臨床的研究. 第1報新潟県下の疫学調査と免疫学的研究. 厚生省特定疾患・肺線維症研究班, 昭和49年度研究報告書p17. 1975.
 
2) 近藤有好, 他:特発性間質性肺炎(IIP)の疫学調査 (II) . 厚生省特定疾患「びまん性肺疾患」調査研究班平成4年度研究報告書. p11-18. 1993.
 
3) 本間行彦, 他:北海道特定事業よりみたIIPの発生率13年間の経緯. 厚生省特定疾患「びまん性肺疾患」調査研究班平成4年度研究報告書.p202～204. 1993.
 
4) 千田金吾, 他:本邦における特発性間質性(IIPs)の実態. 厚生省特定疾患「びまん性肺疾患」調査研究班平成13年度研究報告書.p106-108. 2002.
 
5) 永井正規, 他:電子入力された臨床調査個人票に基づく特定疾患治療研究医療受給者調査報告書. 厚生労働省特定疾患の疫学に関する研究報告書. 2005.
 
6) 大野彰二, 他:臨床調査個人票に基づく特発性間質性肺炎の全国疫学調査, 日呼吸会誌 45:759-764, 2007.
Medical*Online
7) Iwai K, et al:Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Repir Crit Care Med 150:670-675, 1994.
 
8) Miyake Y, et al:Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 49:259-265, 2005.
PubMed
9) Cherniack R M, et al:Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis Am Rev Respir Dis 144:892-900, 1991.
PubMed
10) Coultas D B, et al:The epidemiology of interstitial lung diseases Am J Repir Crit Care Med 150:967-972, 1994
 
11) Raghu G et al:Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 174:810-816, 2006.
PubMed
12) Bjoraker J A, et al:Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Repir Crit Care Med 157:199-203, 1998.
 
13) Gribbin J, et al:Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980-985, 2006.
PubMed
14) Hodgson U, et al:Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis:evidence of founder effect among multiplex families in Finlan. Thorax 57:338-342, 2002.
 

第2章 病理・病態生理

P.32 掲載の参考文献
1) Travis WD, et al:Atlas of Non-Tumor Pathology. Non-Neoplastic Disordfers of the Lower Respiratory Tract. pp939. AFIP, Washington DC, 2002.
 
2) Katzenstein A L A:Surgical Pathology of Non-Neopalstic Lung Disease. 4th Ed, pp502. WB Saunders, Philadelphia, 2006.
 
3) 泉 孝英 監:びまん性肺疾患の臨床. 診断・管理・治療と症例. 第3版, pp320, 金芳堂, 京都, 2003.
 
4) 長井苑子, 他:米国胸部学会ガイドライン間質性肺疾患ガイドライン. pp149. 医学書院東京, 2003.
 
5) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編:特発性間質性肺炎診断と治療の手引き. pp89. 南江堂, 東京, 2004.
 
6) American Thoracic Society:Idiopathic pulmonary fibrosis:Diagnosis and treatment. Am J Respir Crit Care Med t61:646-664, 2000.
 
7) American Thoracic Society/European Respiratory Soceity International Multidiscipli-nary Consensus Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
 
8) Ohtani Y, et al:Chronic bird fancier:s lung:histological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60:665-671, 2005.
 
9) 北市正則, 他:特発性間質性肺炎 (IIPs) のATS/ERS国際分類(2002)-UIPの病理診断を中心に. 呼吸と循環52:413-417, 2004.
 
10) Kitaichi M, et al:S. Pulmonary pathology in association with connective tissue disor. ders. Curr Diag Pathol 10:291-303, 2004.
 
11) 北市正則, 他:非特異性間質性肺炎(NSIP)の病理:間質性肺炎の定量的病型診断方法の紹介を含めて. 病理と臨24:828-834, 2006.
 
12) Wilson J W, et al:Changes in pulmonary fibrosis:8.The need for an international registry for idiopathic pulmonary fibrosis. Thorax 63:285-287, 2008.
 
P.40 掲載の参考文献
1) American Thoracic Society/European Respiratory Society:International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
PubMed
2) 海老名雅仁, 他:難治性・線維性非特異性間質性肺炎 (severe/fatal fibrotic non-specific interstitial pneumonia) の提唱とその患者群の臨床・病理学的検討. 厚生労働省科学研究びまん性肺疾患に関する調査研究班 平成19年度報告書 81-86, 2008.
 
3) 海老名雅仁, 他:特発性肺線維症患者肺の血管・リンパ管構築変化による急性増悪の発症機序. 厚生労働省科学研究 びまん性肺疾患に関する調査研究班 平成18年度報告書 105-112, 2007.
 
4) Ebina M, et al:Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169:1203-1208, 2004.
PubMed
5) Ebina M:Remodeling of airway walls in fatal asthmatics decreases lymphatic distribution; beyond thickening of airway smooth muscle layers. Allergology International 57 (2):1-10 (in press), 2008.
 
6) Mura M, et al:Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 97:1605-1617, 2004.
PubMed
7) Abeyama K, et al:The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267-1274, 2005.
 
8) Ohshimo S, et al:KL-6, a human MUC1 mucin, promotes proliferation and survivalof lung fibroblasts. Biochem Biophys Res Commun 338:1845-1852, 2005.
 
P.49 掲載の参考文献
1) American Thoracic Society:Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2 Pt 1):646-664, 2000.
 
2) American Thoracic Society/European Respiratory Society:American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
PubMed
3) Horowitz J C, et al:Idiopathic pulmonary fibrosis:new concepts in pathogenesis and implications for drug therapy. Treat Respir Med 5:325-342, 2006.
PubMed
4) Maher T M, et al:Idiopathic pulmonary fibrosis:multiple causes and multiple mechanisms? Eur Respir J 30:835-839, 2007.
PubMed
5) Crystal R G, et al:Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 85:769-788, 1976.
PubMed
6) Selman M, et al:Idiopathic pulmonary fibrosis:prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136-151, 2001.
PubMed
7) Selman M, et al:The epithealial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary firosis. Am J Respir Cell Mol Biol 29 (3 Suppl):S93-97, 2003.
 
8) Strieter R M:Pathogenesis and natural history of usual interstitial pneumonia:the whole story or the last chapter of a long novel Chest 128 (5 Suppl 1):526S-532S, 2005.
PubMed
9) Zuo F, et al:Gene expression analysis reveals matrilysin as a key regulator of pul monary fibrosis in mice and humans. Proc Natl Acad Sci USA 99:6292-6297, 2002.
 
10) Krause D S, et al:Multi-organ, multi-lineage engraftment by a single bonemarrow-derived stem cell. Cell 105:369-377, 2001.
 
11) Gharaee-Kermani M, et al:New insightsinto the pathogenesis and treatment of idiopathic pulmonary fibrosis:apotential role for stem cells in the lung parenchyma andimplications for therapy. Pharm Res 24:819-841, 2007.
 
12) Krause D S:Bone Marrow-derived Cells and Stem Cells in Lung Repair. Proc Am Thorac Soc 5:323-327, 2008.
PubMed
13) Hashimoto N, et al:Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 113:243-252, 2004.
PubMed
14) Willis B C, et al:Induction of epithelial-mesenchymal transition in alveolar epithelialcells by transforming growth factor-betal:potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321-1332, 2005.
 
15) Willis B C, et al:Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3:377-382, 2006.
PubMed
16) Wynn T A:Fibrotic disease and the T(H) 1/T(H) 2paradigm. Nat Rev Immunol 4:583-594, 2004.
 
17) Keane MP, et al:The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159:1437-1443, 1997.
PubMed
18) Martinez F J:Idiopathic interstitial pneumonias:usual interstitial pneumonia versusnonspecific interstitial pneumonia. Proc Am Thorac Soc 3:81-95, 2006.
PubMed
19) Flaherty K R, et al:Histopathologic variability in usual and nonspecific interstitialpneumonias. Am J Respir Crit Care Med 164:1722-1727, 2001.
PubMed
20) Yang I V, et al:Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 175:45-54, 2007.
PubMed
21) Rosas IO, et al:When it comes to genes-IPF or NSIP, familial or sporadic-they're all the same. Am J Respir Crit Care Med 175:5-6, 2007.
 

第3章 診断

P.59 掲載の参考文献
1) American Thoracic Society. Idiopathic pulmonary fibrosis:Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646-664, 2000.
PubMed
2) American Thoracic Society:ATS/ERS International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, Am J Respir Crit Care Med 165:277-304, 2002,
PubMed
3) 日本呼吸器学会びまん性肺疾患 診断・治療ガイドライン作成委員会編:特発性間質性肺炎診断と治療のてびき. 南江堂, 東京, 2005.
 
4) 田口善夫, 他:臨床診断基準における主要症状および身体所見について. 厚生科学研究特定疾患対策事業 びまん性肺疾患調査研究班 平成12年度研究報告書 pp96-99. 2002.
 
5) Silva C I, et al:Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis:changes in pattern and distribution of dis-ease over time. Radiology 247:251-259, 2008
 
6) Kinder BW, et al:Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133:226-232, 2008.
PubMed
7) King T E Jr, et al:Idiopathic pulmonary fibrosis:relationship between histopathologic features and mortality. Am J Respir Crit Care Med 464:1025-1032, 2001.
 
8) Raghu G, et al:The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease:Aprospective study. Chest 116 (5):1168-1174, 1999.
 
9) Hunninghake G W, et al:Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 (2):193-196, 2001.
 
10) Nicholson A G, et al:Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 59:500-505, 2004.
PubMed
11) Kondoh Y, et al:Acute exacerbation of interstitial pneumonia following surgical lungbiopsy. Respir Med 100:1753-1759, 2006.
PubMed
12) Collard H R, et al:Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636-643, 2007.
PubMed
P.70 掲載の参考文献
1) American Thoracic Society, European Respiratory Society:Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646-664, 2000.
PubMed
2) 富田友幸:換気力学. 症状・疾患からみた呼吸機能検査の利用法 (谷合哲, 他編), p. 38. 克誠堂出版,東京, 2000.
 
3) 坪井永保, 他:特発性間質性肺炎患者に対するトレッドミル定速歩行試験の妥当性に関する検討. 臨呼吸生理38:77-83, 2006.
 
4) Raghu G, et al:Aplacebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350:125-133, 2004.
 
5) Gahl W A, et al:Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metabol 76:234-242, 2002.
 
6) Latsi P I, et al:Fibrotic idiopathic interstitial pneumonia-the prognostic value of lon-gitudinal functional trends-. Am J Respir Crit Care Med 168:531-537, 2003.
 
7) Hamada K, et al:Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131:650-656, 2007.
PubMed
8) Eaton T, et al:Six-minute walk, maximal exercise tests-? reproducibility in fibrotic in? terstitial pneumonia-. Am J Respir Crit Care Med 171:1150-1157, 2005.
 
9) Lettieri C J, et al:Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746-752, 2006.
PubMed
10) Flaherty K R, et al:Idiopathic pulmonary fibrosis-prognostic value of changes in physiology and six-minute-walk test-. Am J Respir Crit Care Med 174:803-809, 2006.
PubMed
P.78 掲載の参考文献
1) Kohno N, et al:New serum indicator of in-terstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96 (1):68-73, 1989.
 
2) Kuroki Y, et al:Elevated levels of lung sur-factant protein A in sera from patients with idiopathic pulmonary fibrosis and pul-monary alveolar proteinosis. Am Rev Respir Dis 147 (3):723-729, 1993.
 
3) Honda Y, et al:Pulmonary surfactant pro-tein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152 (1):1860-1866, 1995.
 
4) Takahashi H, et al:Serum surfactant pro-teins A and D as prognostic factors in idio:pathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162 (1):1109-1114, 2000.
 
5) Ohnishi H, et al:Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165 (3):378-381, 2002.
 
6) 高橋弘毅, 他:間質性肺炎に対するCyclosporin A 長期使用例の検討. 厚生労働科学研究:特発性肺線維症の予後改善を目指したサイクロスポリン+ステロイド治療ならびにNアセチルシステイン吸入両方に関する臨床研究班. H19年度班研究報告書 (印刷中)
 
7) Takahashi H, et al:Monitoring markers of disease activity for interstitial lung dis-eases with serum surfactant proteins A and D. Respirology 11 (Suppl):S51-54, 2006.
 
8) Ohtani Y, et al:Clinical features of recurrent and insidious chronic bird fancier:s lung. Ann Allergy Asthma Immunol 90 (6):604-610, 2003.
 
P.85 掲載の参考文献
1) American Thoracic Society and European Respiratory Society:American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165 (2):277-304, 2002.
PubMed
2) Sakai S, et al:Lung cancer associated with diffuse pulmonary fibrosis:CT-pathologic correlation. J Thorac Imaging 18 (2):67-71, 2003.
PubMed
3) Nishimoto Y, et al:Detectability of various sizes of honeycombing cysts in an inflated and fixed lung specimen:the effect of CT section thickness. Korean J Radiol 6 (1):17-21, 2005.
 
4) Martinez F J:Idiopathic interstitial pneumonias:usual interstitial pneumonia versus nonspecific interstitial pneumonia. Proc Am Thorac Soc 3 (1):81-95, 2006.
PubMed
5) Gross T J, et al:Idiopathic pulmonary fibrosis. N Engl J Med 345 (7):517-525, 2001.
PubMed
P.94 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患 診断・治療ガイドライン作成委員会:特発性間質性肺炎診断と治療の手引き. 南光堂, 東京, 2004.
 
2) 上甲 剛:画像を中心とした間質性肺炎の疫学調査に関する研究 厚生労働省科学研究費補助金難治性疾患克服事業びまん性肺疾患調査研究班 平成16年度研究報告書, 59-62, 2005.
 
3) 田口善夫, 他:臨床診断基準における主要症状および身体所見について. 2001年厚生科学研究特定疾患対策事業報告書, 96-99, 2001.
 
4) 吉澤靖之:慢性過敏性肺炎と特発性肺線維症の類似性. アレルギー57 (2):95-101, 2008.
 
5) 独立行政法人労働者健康福祉機構編:アスベスト関連疾患日常診療ガイド特発性間質性肺炎診断と治療の手引き. 南光堂, 東京, 2004.
 
6) 小倉高志, 他:MPO-ANCA 陽性間質性肺炎の臨床像. 日胸67 (3):189-201, 2008
 
7) 金沢 実, 他:特発性肺線維症例でのMPO-ANCA陽性群, 陰性群の臨床像の比較および陽性群における治療の必要性の研究. 2003年厚生科学研究特定疾患対策事業報告書, 101-104, 2003.
 
8) Kondoh Y, et al:Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103:1808-1812, 1993.
PubMed

第4章 管理・治療

P.104 掲載の参考文献
1) Idiopathic pulmonary fibrosis:Diagnosis and treatment International consensus statement The Joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) . Am J Respir Crit Care Med 161 (2):646-664, 2000.
 
2) American Thoracic Society/American Thoracic Scoiety International Multidisciplinary consensus classfication of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
 
3) King T E Jr, et al:Idiopathic pulmonary fibrosis:relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164 (6):1025-1032, 2001.
PubMed
4) Selman M, et al:About its pathogenesis and implications to therapy. Ann Intern Med 134:136-151, 2001.
PubMed
5) Kim D S, et al:Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (4):285-292, 2006.
PubMed
6) Martinez F J, et al:The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (12 Pt 1):963-967, 2005.
 
7) Hamada K, et al:Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis. Chest 131:650-656, 2007.
PubMed
8) Collard H R, et al:Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (7):636-643, 2007.
PubMed
9) Flaherty K R, et al:Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164 (9):1722-1727, 2001.
PubMed
10) Kim D S, et al:Idiopathic nonspecific interstitial pneumonia An unrecognized autoimmune disease? Am J Respir Crit Care Med 176:632-633, 2007.
PubMed
11) King T E Jr, et al:Predicting survival in idiopathic pulmonary fibrosis:scoring system and survival model. Am J Respir Crit Care Med 164 (7):1171-1181, 2001.
PubMed
12) Flaherty K R, et al:Idiopathic pulmonary Fibrosis:prognostic value of changes in physiology and six-minute-walk test Am J Respir Crit Care Med 174:803-809, 2006,
PubMed
13) Nagai S, et al:Clinical courses of asymptomatic cases with idiopathic pulmonary fibrosis and a histology of usual interstitial pneumonia. Eur Respir J 11:131s, 1998.
 
14) Gay S E, et al:Idiopathic pulmonary fibrosis:predicting response to therapy and survival. Am J Respir Crit Care Med 157 (4Pt 1):1063-1072, 1998.
 
15) Richeldi L, et al:Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (3):CD002880, 2003.
PubMed
16) 長井苑子:間質性肺疾患の外来診療, 特発性間質性肺炎の鑑別と治療管理, p55-77. 医学書院, 東京, 2007.
 
17) Raghu G, et al:Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis:aprospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144 (2):291-296, 1991.
 
18) Collard HR, et al:Brown KK Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 125(6):2169-2174, 2004.
 
19) Kolb M, et al:Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 12 (6):1409-1414, 1998.
PubMed
20) Dougla W W R, et al:Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the lung study group. Am J Respir Crit Care Med 158:220-225, 1998.
 
21) Ziesche R, et al:Apreliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341:1264-1269, 1999.
 
22) Raghu G, et al:Aplacebo-controlled trial of illterferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350:125-133, 2004.
 
23) King T E Jr, et al:Analyses of ethcacy end points in a controlled trial of interferongammalb for idiopathic pulmonary fibrosis. Chest 127:171-177, 2005.
 
24) Antoniou K M, et al:Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 28:496-504, 2006.
PubMed
25) Bajwa E K, et al:Interferon-gamma1b therapy in idiopathic pulmonary frosis:A metaanalysis. Chest 128:203-206, 2005.
PubMed
26) Raghu G, et al:Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone:Results of a prospective, open-label phase ii study. Am J Respir Crit Care Med 159:1061-1069, 1999.
PubMed
27) Nagai S, et al:Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41:1118-1123, 2002.
PubMed
28) Azuma A, et al:Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040-1047, 2005.
PubMed
29) Handa T, et al:Incidence of pulmonary hypertension and its clinical relevance in patients with interstitial pneumonias:comparison between idiopathic and collagen vascular disease associated interstitial pneumonias. Intern Med 46:831-837, 2007.
PubMed
30) Lok S S:Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis:apotential advantage to patients. Greater Manchester Lung Fibrosis Consortium. J Heart Lung Transplant 18 (9):884-890, 1999.
 
31) Mason D P, et al:Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 84 (4):1121-1128, 2007.
PubMed
P.111 掲載の参考文献
1) American Thoracic Society, European Respiratory Society:ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
PubMed
2) 日本呼吸器学会びまん性肺疾患 診断・治療ガイドライン作成委員会編:特発性間質性肺炎 診断と治療の手引き. 南江堂.東京,2004.
 
3) Nathan S D, et al:Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131:657-663, 2007.
PubMed
4) Hamada K, et al:Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131:650-656, 2007.
PubMed
5) Hallstrand T S, et al:The timed walk test as a measure of severity and survivaal in idiopathic pulmonary fibrosis. Eur Respir J 25:96-103, 2005.
PubMed
6) Lama V N et al:Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med f68:1084-1090, 2003.
 
7) Alakhras M, et al:Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 131:1448-1453, 2007.
PubMed
8) Enomoto N, et al:quantitative analysis of fibroblastic fbci in usual interstitial pneumonia Chest 130:22-29, 2006.
 
9) Flaherty K B, et al:Prognostic implications of physiologic and radiologic changes in idiopathic pulmonary fibrosis. Am J Respir Crit Carec Med 168:543-548, 2003.
 
10) Flaherty K R, et al:Clinical significance of histological classification of idiopathic inter-stitial pneumonia Eur Respir J 19:275-283, 2002.
 
11) Azuma A, et al:Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040-1047, 2005.
PubMed
12) Demedts G W, et al:High-dose acetylcys-teine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229-2242, 2005.
 
13) King T E, et al:BUILD-1:arandomized placebo-controlled trial of bosentan in idio-pathic pulmonary fibrosis. Am J Crit Care Med 177:75-81, 2008.
 
14) King T E, et al:Analyses of efficacy end points in a controlled trial of interferon-γ for idiopathic pulmonary fibrosis. Chest 127:171-177, 2005.
 
15) Kubo H, et al:Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128:1475-1482, 2005.
PubMed
16) Martinez F J, et al:The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142:963-967, 2005.
PubMed
17) Hyzy R, et al:Acute exacerbation of idio-pathic pulmonary fibrosis. Chest 132:1652-1658, 2007.
 
18) Seo Y, et al:Benificial effect of polymyxin B-immobilized column (PMX) hemoperfu-sion treatment on acute exacerbation of id-iopathic pulmonary fibrosis. Intern Med 45:1033-1038, 2006.
 
P.120 掲載の参考文献
1) American thoracic society:American tho-racic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
 
2) American thoracic society:Idiopathic Pulmonary Fibrosis:Diagnosis and Treatment. International Consensus Statement Am J Respir Crit Care Med 161:646-664, 2000.
PubMed
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会:特発性間質性肺炎診断と治療の手引き. 南江堂, 東京, 2004.
 
4) 井上義一:間質性肺炎の合併症とその管理の実際.Medical Practice 24:1071-1077, 2007.
Medical*Online
5) Walter N, et al:Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3:330-338, 2006.
PubMed
6) 井上義一:特発性間質性肺炎診断の標準化と問題点. 治療学 40:82, 2006.
 
7) 井上義一:特発性肺線維症:診断と治療の進歩. 分類と診断. 日内会誌94 (6):1032, 2005.
 
P.126 掲載の参考文献
1) Weitzenblum E, et al:Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 44:118-127, 1983.
PubMed
2) Nathan S D, et al:Idiopathic pulmonary fibrosis and pulmonary hypertension:con-necting the dots. Am J Respir Crit Care Med 175:875-880, 2007.
 
3) Handa T, et al:Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 44:319-325, 2005.
PubMed
4) Nadrous H F, et al:Pulmonary hyperten-sion in patients with idiopathic pulmonary fibrosis. Chest 128:2393-2399, 2005.
 
5) Whelan T P, et al:Effect of preoperative pulmonary artery pressure on early sur-vival after lung transplantation for idio-pathic pulmonary fibrosis. J Heart Lung Transplant 24:1269-1274, 2005.
 
6) Hamada K, et al:Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With ldiopathic Pulmonary Fibrosis. Chest 131:650-656, 2007.
 
7) Handa T, et al:Incidence of pulmonary hy-pertension and its clinical relevance in pa-tients with interstitial pneumonias:compar-ison between idiopathic and collagen vas-cular disease associated interstitial pneu-Inonias. Intern Med 46:831-837, 2007.
 
8) Lettieri C J, et al:Prevalence and outcomes of pulmonary arterial hypertension in ad-vanced idiopathic pulmonary fibrosis. Chest 129:746-752, 2006.
 
9) Agarwal R, et al:Noninvasive estimation of clinically asymptomatic pulmonary hyper? tension in idiopathic pulmonary fibrosis. Indian J Chest Dis Allied Sci 47:267-271 2005.
 
10) Leuchte H H, et al:Brain natriuretic pep-tide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170:360-365, 2004.
 
11) Ghofrani H A, et al:Sildenafil for treatment of lung fibrosis and pulmonary hypertension:arandomised controlled trial. Lancet 360:895-900, 2002.
PubMed
12) Collard H R, et al:Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest t 31:897-899, 2007.
 
13) Lama V N, et al:Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:1084-1090, 2003.
PubMed
14) Flaherty K R, et al:Idiopathic pulmonary fibrosis:prognostic value of changes in physiology and six-minute-walk test Am JRespir Crit Care Med 174:803-809, 2006.
PubMed
15) Miyamoto S, et al:Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Am J Respir Crit Care Med 161:487-492, 2000.
PubMed
16) Park S H, et al:Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156:600-608, 1997.
PubMed
17) Sasayama S, et al:Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension, Circ J 69:131-137, 2005. Erratum in:Circ J 69:1007, 2005.
 
18) Channick R N, et al:Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study. Lancet 358:1119-1123, 2001.
PubMed
19) Rubin L J, et al:Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903, 2002. Erratum in:N Engl J Med 346:1258, 2002.
 
20) King T E Jr, et al:BUILD-1:A Random-ized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 177:75-81, 2008.
 
P.132 掲載の参考文献
1) American Thoracic Society:Idiopathic pul-monary fibrosis:diagnosis and treatment. American Thoracic Society (ATS), and the European Respiratory Society (ERS) . Am JRespir Crit Care Med et al 161:646-664, 2000.
 
2) Katzenstein AL, et al:Idiopathic pul-monary fibrosis:clinical relevance of patho-logic classification. Am J Respir Crit Care Med 157:1301-1315, 1998.
 
3) Grutters J C, et al:Genetics of fibrosing lung diseases. Eur Respir J 25 (5):915-927, 2005.
PubMed
4) Acharya P S, et al:Fibroblast activation protein:aserine protease expressed at the remodeling interface in idiopathic pul-monary fibrosis. Hum Pathol 37:352-360, 2006.
 
5) Crystal R G, et al:Future research direc-tions in idiopathic pulmonary fibrosis:summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 166:236-246, 2002.
 
6) Shoda H, et al:Overproduction of collagen and diminished SOCSI expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis. Biochem Biophys Res Commun 353:1004-1010, 2007.
 
7) Armendariz-Borunda J, et al:A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 55:1663-1665, 2006.
PubMed
8) Mesa RA, et al:A phase H trial of pir-fenidone (5-methyl-1-phenyl-2-[1H]-pyri-done), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 114:111-113, 2001.
 
9) Negri A L:Prevention of progressive fibrosis in chronic renal diseases:antifibrotic agents. J Nephrol 17:496-503.
PubMed
10) Raghu G, et al:Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent pirfenidone:results of a prospective, open-label Phase H study. Am J Respir Crit Care Med 159:1061-1069, 1999.
 
11) Nagai S, et al:Open-1abel compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41 (12):1118-1123, 2002.
PubMed
12) Azuma A, et al:Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (9):1040-1047, 2005.
PubMed
13) Ziesche R, et al:Apreliminary study of long-term treatment with interferon gamma-1b. N Engl J Med341:1264-1269, 1999.
 
14) Raghu G, et al:Aplacebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2) 1125-133, 2004.
 
15) Shi-Wen X, et al:Fibroblast matrix gene expression and connective tissue remodeling:role of endothelin-1. J Invest Dermatol 116:417-425, 2001.
PubMed
16) Park S H, et al:Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156:6008, 1997.
 
17) King T E Jr, et al:arandomized placebocontrolled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177:75-81, 2008.
 
P.138 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会付2 厚生労働省特定疾患認定基準 (36. 特発性間質性肺炎) . 特発性間質性肺炎診断と治療の手引き:63-66, 2004.
 
2) Agusti A G, et al:Mechanisms of gas-ex-change impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 143:219-225, 1991.
 
3) Fujimoto S, et al:[Factors contributing to exercise-induced hypoxemia in patients with chronic lung diseases. Nihon Kyobu Shikkan Gakkai Zasshi 32 (Suppl):101-108, 1994.
PubMed
4) King T E Jr, et al:Predicting survival in id-iopathic pulmonary fibrosis:scoring system and survival model Am J Respir Crit Care Med 164:1171-1181, 2001.
 
5) Lederer D J, et al:Six-minute-walk dis-tance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 474:659-664, 2006.
 
6) Lettieri C J, et al:The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 100:1734-1741, 2006.
PubMed
7) Lettieri C J, et al:Prevalence and outcomes qf pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746-752, 2006.
 
8) Hamada K, et al:Signiflcance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131:650-656, 2007.
 
9) Nathan S D, et al:Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131:657-663, 2007.
PubMed
10) Zisman D A, et al:High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 132:773-779, 2007.
 
11) Collard, et al:Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131:897-899, 2007.
PubMed
12) Crockett A J, et al:Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst Rev:CD002883, 2001.
PubMed
13) Douglas W W, et al:Idiopathic pulmonary fibrosis:Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 161:1172-1178, 2000.
PubMed
14) Nishiyama O, et al:Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis:comparison with COPD. Respir Med 101:833-838, 2007.
PubMed
15) Blivet S, et al:Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 120:209-212, 2001.
 
16) Saydain G, et al:Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 166:839-842, 2002.
 
17) Eisner M D, et al:Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 164:231-236, 2001.
PubMed
18) Kobayashi N, et al:[Eighty cases of chronic respiratory failure treated with home noninvasive positive pressure ventilation]. Nihon Kokyuki Gakkai Zasshi 43:3-9, 2005.
PubMed
P.146 掲載の参考文献
1) Global Initiative for Chronic Obstructive Lung Disease:Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease. National Institute of Health, National Heart Lung and Blood Institute. 2001:Update of the management sections, GOLD website (www.goldcopd.com). Date update:July 2003.
 
2) Pulmonaly Rehabilitation Joint ACCP/ AACVPR Evidence-Based Guidelines, AC-CP/AACVPR Pulmonaly Rehabilitation Guidelines Panel. Chest 112:1363-1396, 1997.
 
3) 日本呼吸器学会びまん性肺疾患 診断・治療ガイドライン作成委員会編:特発性間質性肺炎診断と治療の手引き. 南江堂, 東京, 2004.
 
4) Hansen J E, et al:Pathophysiology of activity limitation in patients with interstitial Iung disease. Chest 109:1566-1576, 1996.
 
5) Harris-Eze A O, et al:Role of hypoxia and pulmonary mechanics in exercise limitation in interstitial lung disease. J Respir Crit Care Med 154:994-1001, 1996.
PubMed
6) Nishiyama O, et al:Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 127:2028-2033, 2005.
PubMed
7) 日本呼吸管理学会/日本呼吸器学会/日本理学療法士協会:呼吸リハビリテーションマニュアル-運動療法-. 照林社, 東京, 2003.
 
8) AACVPR:Guide for Pulmonary Rehabilitation programs third edition. Human Kinetics, 73-73, 2005.
 
9) Decramaer M, et al:Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 150:11-16, 1994.
 
10) Swigris JJ, et al:Health-related quality of life in patients with idiopathic pulmonary fibrosis:asystematic review. Thorax 60:588-594, 2005.
 
11) De Veries J, et al:Quality of life idiopathic pulmonary fibrosis patients. Eur Respir J 17:954-961, 2001.
 
12) Martinez TY, et al:Evaluation of the short-form 36 item questionnaire to measure health-related quality of in patients with idiopathic pulmonary fibrosis. Chest 117:1627-1632, 2000.
PubMed
13) Nishiyama O, et al:Health related quality of life in patients with idiopathic pulmonary fublosis. What is the main contributing factor? Respir Med 99:408-414, 2005.
PubMed
14) Tazanakis N, et al:Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med 16:105-112, 2005.
 
15) Foster S, et al:Pulmonary rehabilitation in lung disease other than chronic obstructive pulmonary disease. Am Rev Respir Dis 141:601-604, 1990.
PubMed
16) Holland A E, et al:Short-term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008 (in press)
 
P.153 掲載の参考文献
1) Toronto Lung Transplant Group:Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 314:1140-1145, 1986.
 
2) Date H, et al:Living-donor lobar lung transplantation for primary cilliary dyskinesia. Ann Thorac Surg 71:2008-2009, 2001.
 
3) Trulock E P, et al:Registry of the International Society for Heart and Lung Transplantation:Twenty-fourth official adult lung and heart-lung transplant report-2007. J Heart Lung Transplant 26:782-795, 2007.
PubMed
4) Meyers B F, et al:Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis:a ten-year institutional experience. J Thorac Cardiovasc Surgery 120:99-107, 2000.
 
5) Orens J B, et al:International guidelines for the selection of lung transplant candidates:2006 update-A consensus report from the pulmonary scientific council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745-755, 2006.
PubMed
6) De Meester J, et al:Listing for lung transplantation:1ife expectancy and transplant effect stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 20:518-524, 2001.
 
7) Starnes V A, et al:A decade of living lobar lung transplantation:recipient outcomes. J Thorac Cardiovasc Surg 127:114-122, 2004.
PubMed
8) Date H, et al:Improved survival after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg 128:933-940, 2004.
PubMed
9) Date H, et al:Anew treatment strategy for advanced idiopathic interstitial pneumonia:living-donor lobar lung transplantation. Chest 128:1364-1370, 2005.
 
10) Travis W, et al:Idiopathic nonspecific interstitial pneumonia:prognostic significance of cellular and fibrosing Patterns. Am J Surg Pathol 24:19-33, 2000.
 
P.161 掲載の参考文献
1) American Thoracic Society/European Respiratory Society:American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304, 2002.
PubMed
2) Kim D S, et al:Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:285-292, 2006.
PubMed
3) Rudd R M, et al:British thoracic society study on cryptogenic fibrosing alveolitis:response to treatment and survival. Thorax 62:62-66, 2007.
 
4) Hamada K, et al:Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131:650-656, 2007.
PubMed
5) Jeon K, et al:Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respir Med 100:451-457, 2006.
PubMed
6) Martinez F J, et al:The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142:963-967, 2005.
PubMed
7) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会:厚生労働科学研究特定疾患対策事業びまん性肺疾患研究班 特発性間質性肺炎の診断・治療ガイドライン. 日呼吸会誌 43:179-207, 2005.
 
8) Lettieri C J, et al:Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746-752, 2006.
PubMed
9) Tomioka H, et al:Health-related quality of life in patients with idiopathic pulmonary fibrosis.-Cross-sectional and longitudinal study-. Intern Med 46:1533-1542, 2007.
PubMed
10) King T E Jr, et al:Idiopathic pulmonary fibrosis:relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164:1025-1032, 2001.
PubMed
11) Nicholson A G, et al:The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166:173-177, 2002.
PubMed
12) Tiitto L, et al:Relationship between histopathologic features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 61:1091-1095, 2006.
 
13) Antoniou K M, et al:Idiopathic pulmonary fibrosis. Outcome in relation to smoking status. Am J Respir Crit Care Med 177:190-194, 2008.
PubMed
14) Flaherty K R, et al:Radiological versus histological diagnosis in UIP and NSIP:survival implications. Thorax 58:143-148, 2003.
PubMed
15) Lynch D A, et al:High-resolution computed tmography in idiopathic pulmonary fibrosis. Diagnosis and prognosis. Am J Respir Crit Care Med 172:488-493, 2005.
 
16) Takahashi H, et al:Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent Am J Respir Crit Care Med 162:110-1114, 2000.
 
17) Greene K E, et al:Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 19:439-446, 2002.
 
18) Yokoyama A, et al:Prognostic value of circulationg KL-6 in idiopathic pulmonary fibrosis. Respirology 11:164-168, 2006.
 
19) Latsi P I, et al:Fibrotic idiopathic interstitial pneumonia The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:531-537, 2003.
PubMed
20) Collard H R, et al:Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:538-542, 2003.
PubMed
21) Flaherty K R, et al:Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:543-548, 2003.
PubMed
22) Jegal Y, et al:Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171:639-644, 2005.
PubMed
23) King T E Jr, et al:Analyses of efficacy end points in a controlled trial of interferongamma lb for idiopathic pulmonary fibrosis. Chest 127:171-177, 2005.
 
24) King Jr T E, et al:Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med 164:1171-1181, 2001.
 
25) Wells A U, et al:Idiopathic pulmonary fibrosis. A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167:962-969, 2003.
PubMed
26) Lederer D J, et al:Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:659-664, 2006.
PubMed
27) Lettieri C J, et al:The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med 100:1734-1741, 2006.
PubMed
28) Lama V N, et al:Prognostic value of desaturation during a 6-minute walk test in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:1084-1090, 2003.
 
29) Flaherty K R, et al:Idiopathic pulmonary fibrosis. Prognostic value of changes in physiology and six-minute-walk test. Am JRespir Crit Care Med 174:803-809, 2006.
PubMed
30) Nadrous H F, et al:Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128:2393-2399, 2005.
PubMed
31) Collard H R, et al:Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636-643, 2007.
PubMed

第5章 ガイドライン

P.170 掲載の参考文献
1) American Thoracic Society. Idiopathic pulmonary fibrosis:diagnosis and treatment. American Thoracic Society (ATS), and the International consensus statement. European Respiratory Society (ERS):Am J Respir Crit Care Med 161 (2 Pt 1):646-664, 2000.
 
2) American Thoracic Society/European Res-piratory Society International Multi-disciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165 (2):277-304, 2002.
 
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会:特発性間質性肺炎診断と治療の手引き. 南江堂, 東京, 2004.
 
4) Flaherty K R, et al:Idiopathic interstitial pneumonia:do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 175:1054-1060, 2007.
PubMed
5) Nicholson A G, et al:Interobserver variation between pathologists in diffuse parenchymal lung disease. Thorax 59:500-505, 2004.
PubMed
6) Flaherty K R, et al:Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164:1722-1727, 2001.
PubMed
7) Flaherty K R et al:Radiological versus histological diagnosis in UIP and NSIP:sur-vival implications. Thorax 58:143-148, 2003.
 
8) Demedts M, et al:IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353:2229-2242, 2005.
 
9) Azuma A, et al:Double-blind, placebo-con:trolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040-1047, 2005.
 
10) Didierlaurent A, et al:Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 205:323-329, 2008.
PubMed

書評

最近チェックした商品履歴

Loading...